Harmony Biosciences (HRMY) CEO discloses stock option exercise and sales

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. reported an insider transaction by its president, CEO and director on a Form 4. On 12/12/2025, the executive exercised a stock option for 20,000 shares of common stock at an exercise price of $8.22 per share, converting the option into shares.

That same day, the executive sold 20,000 shares and an additional 5,933 shares of common stock in open-market transactions under a Rule 10b5-1 trading plan. The reported weighted average sale price was $40.1073 per share, with individual trades occurring between $40.00 and $40.28. Following these transactions, the Form 4 reports 0 shares of common stock and 0 derivative securities beneficially owned directly from this option grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dayno Jeffrey M.

(Last) (First) (Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

630 W GERMANTOWN PIKE, SUITE 215

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		20,000	A	$8.22	20,000	D
Common Stock	12/12/2025		S(1)		20,000	D	$40.1073(2)	0	D
Common Stock	12/12/2025		S(1)		5,933	D	$40.1073(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$8.22	12/12/2025		M			20,000	(3)	11/13/2027	Common Stock	20,000	$0	0	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.28. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The stock option vests in five equal annual installments beginning on November 1, 2018.

	/s/ Christian Ulrich, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Harmony Biosciences (HRMY) report on this Form 4?

The Form 4 reports that the company’s president, CEO and director exercised a stock option for 20,000 shares of Harmony Biosciences common stock at $8.22 per share and sold 20,000 and 5,933 shares of common stock in market transactions on 12/12/2025.

At what prices did the Harmony Biosciences (HRMY) insider sell shares?

The Form 4 reports a weighted average sale price of $40.1073 per share. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.28 per share.

How many Harmony Biosciences (HRMY) shares did the insider own after the reported transactions?

After the reported transactions on 12/12/2025, the Form 4 shows that the reporting person beneficially owned 0 shares of common stock and 0 derivative securities from the reported stock option position.

Was the Harmony Biosciences (HRMY) insider sale under a Rule 10b5-1 trading plan?

Yes. A footnote explains that the sales reported were effected pursuant to a Rule 10b5-1 trading plan, which is a pre-arranged plan for buying or selling securities.

What are the key terms of the Harmony Biosciences (HRMY) stock option exercised?

The derivative table shows a stock option covering 20,000 shares of common stock with an exercise price of $8.22 per share and an expiration date of 11/13/2027. A footnote states the option vests in five equal annual installments beginning on November 1, 2018.

What positions does the reporting person hold at Harmony Biosciences (HRMY)?

According to the Form 4, the reporting person is a director and serves as an officer of Harmony Biosciences Holdings, Inc., with the title president, CEO.